Erin Mayfield, OD
Optometrist · Lamar, MONPI 1104407261
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 40.8% of the total. Reporting peaked in 2023 at $252 and has fallen 56.6% since, to $109 in 2025. That places this record below the midpoint for optometrist clinicians in MO, where the typical reported total is $689.
Across 26 payments — averaging $29.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$314
- Coopervision Inc.$163
- LKC Technologies, Inc.$128
- Sun Pharmaceutical Industries Inc.$68
- Topcon Healthcare, Inc.$26
- Novartis$23
- plus $47 from 3 others
What the payments were for
- Food & beverage$770100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 9 | $314 |
| Coopervision Inc. | 5 | $163 |
| LKC Technologies, Inc. | 3 | $128 |
| Sun Pharmaceutical Industries Inc. | 4 | $68 |
| Topcon Healthcare, Inc. | 1 | $26 |
| Novartis | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| ABB Con-cise Optical Group LLC | 1 | $13 |
| Sanofi | 1 | $13 |
How this compares
$770 in reported general payments places this provider in the 50th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 31 | $33,632 |
| LumiganBimatoprost | 22 | $14,359 |
| Latanoprost | 43 | $680 |
| Timolol Maleate | 12 | $163 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $143 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Lamar
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Alana KellerWildwood$94K
- Sarah HubbardChesterfield$91K
- Ariel CerenzieSaint Louis$76K
- Geoffrey PowellKansas City$55K
- Thomas HobbsSedalia$53K
- Heather WebsterColumbia$52K
- Sean MulqueenyCreve Coeur$45K
- Glen LojkaEllisville$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.